A cross-sectional study describing the current status of diagnosis and treatment of uroepithelial cancer in hospitals of different grades in Henan Province
Adults ≥18 years of age (at enrollment)
Histologically confirmed uroepithelial carcinoma
Patients with newly diagnosed or completed radical uroepithelial carcinoma in the early stages of uroepithelial cancer/advanced unresectable or with distant metastases of urothelial carcinoma
Complete medical history information
Incomplete medical history and medical records
Patients diagnosed with uroepithelial carcinoma attending multiple research center hospitals in Henan Province from January 1, 2023-December 31, 2023
Case-only
Cross-sectional
Not listed
Describing the diagnosis and treatment patterns of patients with early versus advanced uroepithelial carcinoma in different grades of hospitals in Henan Province
To describe the similarities and differences between the way patients with early and advanced uroepithelial cancer are diagnosed and treated in different levels of hospitals in Henan Province and the current guidelines for uroepithelial cancer.
Comparison of differences in diagnosis and treatment patterns between patients with early-stage and advanced uroepithelial carcinoma in county hospitals and different consultation departments of the same hospital in Henan province
The main purpose of this study is to compare the differences between the diagnosis and treatment modalities and guidelines for early and advanced uroepithelial cancer patients in Henan Province in county hospitals. It also compares the differences in treatment modalities between different departments in the same level of hospitals.
Describing the pathology as well as genetic testing of patients with uroepithelial carcinoma in different grades of hospitals in Henan province
1. Proportion of different genes/proteins tested in patients with uroepithelial cancer (mutations in FGFR, HER2, HRR, ARID1A and CREBBP, TP53, CDKN2A and PD-L1 expression) 2. Proportion of early and advanced uroepithelial cancer patients with high expression/mutations of different genes and use of targeted therapies
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
